New Pharmacological Therapies in the Treatment of Epilepsy in the Pediatric Population

被引:0
|
作者
Danilowska, Karolina [1 ]
Picheta, Natalia [1 ]
Zyla, Dominika [1 ]
Piekarz, Julia [1 ]
Zych, Katarzyna [1 ]
Gil-Kulik, Paulina [2 ]
机构
[1] Med Univ Lublin, Students Sci Soc Clin Genet, PL-20080 Lublin, Poland
[2] Med Univ Lublin, Dept Clin Genet, PL-20080 Lublin, Poland
关键词
epilepsy in children; pediatric epilepsy; pharmacological treatment; antiseizure drugs; seizure control; LENNOX-GASTAUT SYNDROME; STATUS EPILEPTICUS; SEIZURES; CANNABIDIOL; CHILDREN; BRIVARACETAM; MANAGEMENT;
D O I
10.3390/jcm13123567
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Epilepsy is a disorder characterized by abnormal brain neuron activity, predisposing individuals to seizures. The International League Against Epilepsy (ILAE) categorizes epilepsy into the following groups: focal, generalized, generalized and focal, and unknown. Infants are the most vulnerable pediatric group to the condition, with the cause of epilepsy development being attributed to congenital brain developmental defects, white matter damage, intraventricular hemorrhage, perinatal hypoxic-ischemic injury, perinatal stroke, or genetic factors such as mutations in the Sodium Channel Protein Type 1 Subunit Alpha (SCN1A) gene. Due to the risks associated with this condition, we have investigated how the latest pharmacological treatments for epilepsy in children impact the reduction or complete elimination of seizures. We reviewed literature from 2018 to 2024, focusing on the age group from 1 month to 18 years old, with some studies including this age group as well as older individuals. The significance of this review is to present and compile research findings on the latest antiseizure drugs (ASDs), their effectiveness, dosing, and adverse effects in the pediatric population, which can contribute to selecting the best drug for a particular patient. The medications described in this review have shown significant efficacy and safety in the studied patient group, outweighing the observed adverse effects. The main aim of this review is to provide a comprehensive summary of the current state of knowledge regarding the newest pharmacotherapy for childhood epilepsy.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Emerging surgical therapies in the treatment of pediatric epilepsy
    Karsy, Michael
    Guan, Jian
    Ducis, Katrina
    Bollo, Robert J.
    TRANSLATIONAL PEDIATRICS, 2016, 5 (02) : 67 - 78
  • [2] Episodic Migraine in the Pediatric Population: Behavioral Therapies and other Non-Pharmacological Treatment Options
    Gazerani, Parisa
    CURRENT PAIN AND HEADACHE REPORTS, 2025, 29 (01)
  • [3] Levetiracetam: Pharmacological properties, safety and efficacy in the pediatric population with epilepsy
    Ansari, Zarrin A. H.
    JOURNAL OF PEDIATRIC NEUROLOGY, 2014, 12 (01) : 1 - 13
  • [4] Rufinamide treatment for refractory epilepsy in a largely pediatric population
    Lee, Jennifer Y.
    Bruno, Patricia
    Rabe, Olivia T.
    Thiele, Elizabeth A.
    Thibert, Ronald L.
    JOURNAL OF PEDIATRIC EPILEPSY, 2012, 1 (02) : 97 - 101
  • [5] PHARMACOLOGICAL TREATMENT OF EPILEPSY
    AUCAMP, AK
    SOUTH AFRICAN MEDICAL JOURNAL, 1979, 56 (15): : 593 - 599
  • [6] Emerging immune therapies in pediatric epilepsy
    Wirrell, E.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [7] New and Emerging Medications for Treatment of Pediatric Epilepsy
    Perry, M. Scott
    PEDIATRIC NEUROLOGY, 2020, 107 : 24 - 27
  • [8] Searching for new targets for treatment of pediatric epilepsy
    Noam, Yoav
    Raol, Yogendra H.
    Holmes, Gregory L.
    EPILEPSY & BEHAVIOR, 2013, 26 (03) : 253 - 260
  • [9] Pharmacological therapies for the treatment of osteoarthritis
    McColl, GJ
    MEDICAL JOURNAL OF AUSTRALIA, 2001, 175 : S108 - S111
  • [10] THE EFFECTIVENESS OF TREATMENT CHOICES FOR REFRACTORY EPILEPSY AMONG PEDIATRIC POPULATION
    Pan, I
    Lam, S.
    VALUE IN HEALTH, 2019, 22 : S366 - S366